Kleynerman A, Rybova J, Faber M, McKillop W, Levade T, Medin J
Biomolecules. 2023; 13(2).
PMID: 36830643
PMC: 9953133.
DOI: 10.3390/biom13020274.
Li G, Kidd J, Gehr T, Li P
Cell Physiol Biochem. 2021; 55(S4):13-34.
PMID: 33861526
PMC: 8193717.
DOI: 10.33594/000000356.
Meyer-Schwesinger C
Cell Tissue Res. 2021; 385(2):371-392.
PMID: 33433692
PMC: 8523507.
DOI: 10.1007/s00441-020-03375-7.
Kyriakou K, Lederer C, Kleanthous M, Drousiotou A, Malekkou A
Int J Mol Sci. 2020; 21(5).
PMID: 32111095
PMC: 7084529.
DOI: 10.3390/ijms21051607.
Yu F, Amintas S, Levade T, Medin J
Orphanet J Rare Dis. 2018; 13(1):121.
PMID: 30029679
PMC: 6053731.
DOI: 10.1186/s13023-018-0845-z.
Chronic lung injury and impaired pulmonary function in a mouse model of acid ceramidase deficiency.
Yu F, Islam D, Sikora J, Dworski S, Gurka J, Lopez-Vasquez L
Am J Physiol Lung Cell Mol Physiol. 2017; 314(3):L406-L420.
PMID: 29167126
PMC: 5900354.
DOI: 10.1152/ajplung.00223.2017.
Podocyte pathology and nephropathy - sphingolipids in glomerular diseases.
Merscher S, Fornoni A
Front Endocrinol (Lausanne). 2014; 5:127.
PMID: 25126087
PMC: 4115628.
DOI: 10.3389/fendo.2014.00127.
On-tissue localization of ceramides and other sphingolipids by MALDI mass spectrometry imaging.
Jones E, Dworski S, Canals D, Casas J, Fabrias G, Schoenling D
Anal Chem. 2014; 86(16):8303-11.
PMID: 25072097
PMC: 4139181.
DOI: 10.1021/ac501937d.
Respiratory manifestations in patients with inherited metabolic diseases.
Santamaria F, Montella S, Mirra V, De Stefano S, Andria G, Parenti G
Eur Respir Rev. 2013; 22(130):437-53.
PMID: 24293461
PMC: 9639176.
DOI: 10.1183/09059180.00008012.
Spinal muscular atrophy associated with progressive myoclonic epilepsy is caused by mutations in ASAH1.
Zhou J, Tawk M, Tiziano F, Veillet J, Bayes M, Nolent F
Am J Hum Genet. 2012; 91(1):5-14.
PMID: 22703880
PMC: 3397266.
DOI: 10.1016/j.ajhg.2012.05.001.
Farber disease with prolonged survival.
Fiumara A, Nigro F, Pavone L, Moser H
J Inherit Metab Dis. 1993; 16(5):915-6.
PMID: 8295420
DOI: 10.1007/BF00714300.
Substrate-specificities of acid and alkaline ceramidases in fibroblasts from patients with Farber disease and controls.
Momoi T, NADLER H
Biochem J. 1982; 205(2):419-25.
PMID: 6814427
PMC: 1158496.
DOI: 10.1042/bj2050419.
Fatty acid composition of free ceramides of kidney and cerebellum from a patient with Farber's disease.
Sugita M, Connolly P, DULANEY J, Moser H
Lipids. 1973; 8(7):401-6.
PMID: 4740649
DOI: 10.1007/BF02531715.
Sphingolipids and their precursors in human brain (normal and MS).
Gerstl B, TAVASTSTJERNA M, Eng L, Smith J
Z Neurol. 1972; 202(2):104-20.
PMID: 4115920
DOI: 10.1007/BF00316160.
A case of lipogranulomatosis Farber: some clinical and ultrastructural aspects.
Burck U, Moser H, Goebel H, GRUTTNER R, Held K
Eur J Pediatr. 1985; 143(3):203-8.
PMID: 3987715
DOI: 10.1007/BF00442139.
Farber's disease in two siblings, sural nerve and subcutaneous biopsies by light and electron microscopy.
Pellissier J, BERARD-BADIER M, Pinsard N
Acta Neuropathol. 1986; 72(2):178-88.
PMID: 3103372
DOI: 10.1007/BF00685981.
A specific ultrastructural marker for disseminated lipogranulomatosis (Faber).
Schmoeckel C, Hohlfed M
Arch Dermatol Res. 1979; 266(2):187-96.
PMID: 230790
DOI: 10.1007/BF00694628.
